02 May 2024
ALN-APP study: who can participate and why?
We are getting closer to a drug study with ALN-APP and Dutchtype CAA in Perth. The so-called cAPPricorn-1 study will take place in 60 countries and start in Canada soon. Because the first participants with sporadic CAA will soon enroll, part of the protocol is placed online. Because this information is now public, we'd like to take the opportunity to inform you about choices that were made for the study about who can participate and why.
Read more